DEF: Baxter Navigates Turnaround Amid Challenging 2025

Baxter International Inc. reports a challenging 2025 with significant leadership changes and strategic divestitures, as it embarks on a turnaround strategy.

Summary

• The company completed the sale of its Kidney Care business (Vantive Health LLC) to Carlyle Group Inc. on January 31, 2025, generating approximately $3.3 billion in net after-tax proceeds, marking the final piece of strategic transformation initiatives announced in January 2023.
• Andrew Hider was appointed President and CEO in August 2025, with Brent Shafer transitioning to Non-Executive Chair, separating the roles.
• Financial results for 2025 from continuing operations include Adjusted Net Sales of $11.2 billion (up 6% from 2024), Adjusted EPS of $2.27 (up 20% from 2024), Operating Cash Flow of $951 million (up 16% from 2024), and Free Cash Flow of $438 million (up 17% from 2024).
• GAAP Earnings per Share for 2025 was negative ($1.75).
• Annual incentive plan payouts for 2025 ranged from 52% to 61% of target, reflecting Adjusted Net Sales at 97.6% of target, Adjusted EPS at 85.8% of target, and Free Cash Flow at 44.5% of target.
• Long-term incentive (PSU) payout for the cycle ending December 31, 2025, was 57% of target, with Adjusted ROIC at 87% of target and Adjusted Net Sales CAGR at 102% of target, but Relative TSR was at the 3rd percentile rank.
• The company is seeking stockholder approval for the Second Amended and Restated 2021 Incentive Plan, which would increase the number of shares authorized for issuance by 20,000,000.
• A proposal to amend the Certificate of Incorporation to reduce the minimum number of directors from nine to seven is also on the ballot for stockholder approval.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to significant underperformance in TSR and key financial metrics (EPS, FCF) against targets and market benchmarks, despite ongoing strategic transformation efforts and new leadership. The acknowledged 'challenging year' and 'early stages of a turnaround' indicate continued headwinds.

Positives

• Completed the strategic sale of the Kidney Care business, generating approximately $3.3 billion in net after-tax proceeds, which was the final step in a major transformation.
• Introduced several new products and solutions, including the Welch Allyn Connex 360 Vital Signs Monitor, Voalte Linq with Scotty assistant, and room-temperature Hemopatch Sealing Hemostat.
• Successfully executed recovery actions following Hurricane Helene, restoring IV solution inventory levels and removing product allocations by May 2025.
• Received a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for IV Solutions, Nutrition Solutions, and Premix Drugs.
• Expanded participation in customer supply-assurance programs, including a collaboration with Vizient Inc. for IV fluids.
• Demonstrated commitment to corporate responsibility by publishing the 2024 Corporate Responsibility Report and renewing a $2.6 million grant for STEM programs.
• Adjusted Net Sales from continuing operations increased by 6% and Adjusted EPS by 20% in 2025 compared to 2024.
• Operating Cash Flow increased by 16% and Free Cash Flow by 17% in 2025 compared to 2024.
• The Board implemented strong corporate governance practices, including separating the Chair and CEO roles, robust board refreshment, and active committee chair rotation.
• Amended stock ownership guidelines to implement additional executive stock retention requirements in response to stockholder feedback.

Negatives

• The company experienced a challenging year and is in the early stages of a turnaround, as stated by the new CEO.
• GAAP Earnings per Share for 2025 was negative ($1.75).
• Overall TSR performance was significantly negative over the past three years (-60%) and five years (-74%), underperforming both the S&P 500 Composite Index and the S&P 500 Health Care Index.
• Free Cash Flow From Continuing Operations for 2025 was only 44.5% of its annual incentive target, indicating underperformance in cash generation.
• Adjusted EPS From Continuing Operations for 2025 was 85.8% of its annual incentive target.
• Relative TSR for the 3-year PSU cycle ending 2025 was at the 3rd percentile rank, indicating significant underperformance against peers.
• Two new regulatory actions occurred in 2025, impacting the 'Quality Metrics' individual performance assessment.

Risks

• Macroeconomic and operational challenges, including global tariffs and clinical practice changes, continue to impact financial performance.
• The company is in the early stages of a turnaround, indicating ongoing uncertainty and potential for further challenges in stabilizing business performance and achieving long-term growth.
• Reliance on the successful execution of the Baxter Growth and Performance System (GPS) and refined operating model to reduce complexity, improve decision-making, and enhance execution.
• Potential for significant costs and disruptions if a new independent auditor were to be retained, as highlighted by the Audit Committee.
• Failure to attract, retain, and motivate highly skilled and critical talent if the proposed incentive plan (Proposal 4) is not approved, potentially leading to increased cash compensation and reduced alignment with stockholder interests.
• The risk of not maintaining an optimal number of directors if the Board size amendment (Proposal 5) is not approved, potentially hindering effective decision-making and board refreshment during transitional periods.

Future Outlook

The company is in the early stages of a turnaround, focusing on stabilizing business performance, strengthening execution, thoughtful capital allocation, and long-term value creation. Management has launched the Baxter Growth and Performance System (GPS) and refined its operating model to reduce complexity, accelerate decision-making, and improve execution. The vision is to redefine healthcare delivery across the care journey, with refreshed sustainability commitments expected after the 2025 Corporate Responsibility Report.

Management Comments

• Andrew Hider, President and CEO: 'This past year was challenging for the company and we are in the early stages of a turnaround.'
• Andrew Hider, President and CEO: 'My focus has been clear: to listen and learn, engage deeply across the organization and with our customers and stockholders, and lead decisively, building on Baxters solid foundation while positioning the company for long-term success.'
• Andrew Hider, President and CEO: 'Baxter remains focused on stabilizing business performance, strengthening execution, thoughtful capital allocation and long-term value creation, guided by our Mission and supported by a resilient, dedicated global team.'
• Brent Shafer, Non-Executive Chair of the Board: 'This past year has been a challenging year for the company, and it was also a year of tremendous change.'
• Brent Shafer, Non-Executive Chair of the Board: 'The full Board is supportive of the actions Andrew and the management team are taking to set a new clear path forward and deliver meaningful impact for customers, patients and long-term value creation for stockholders.'

Industry Context

StockSavvy.ai notes that Baxter's strategic transformation, including the divestiture of its Kidney Care business, aligns with a broader industry trend among diversified healthcare companies to streamline portfolios and focus on core, higher-growth segments. The emphasis on connected monitoring devices (Welch Allyn Connex 360) and communication solutions (Voalte Linq) reflects the increasing digitalization of healthcare and the demand for integrated care platforms. The challenges faced, such as macroeconomic pressures and supply chain disruptions (Hurricane Helene), are common across the global healthcare manufacturing sector, highlighting the importance of operational resilience and diversified supply chains. The company's underperformance in TSR compared to the S&P 500 Health Care Index suggests it has lagged behind peers in capitalizing on these trends or mitigating industry headwinds.

Comparison to Industry Standards

• Baxter's 3-year Total Shareholder Return (TSR) of (60%) significantly underperformed the S&P 500 Composite Index (86%) and the S&P 500 Health Care Index (20%), indicating a substantial lag compared to broader market and healthcare sector benchmarks.
• The Relative TSR for the 3-year PSU cycle ending 2025 was at the 3rd percentile rank against the S&P 500 Healthcare Equipment & Services Index, demonstrating poor performance relative to direct industry competitors.
• The company's burn rate of 1.3% (three-year average) is considered reasonable compared to comparator companies, suggesting efficient use of equity awards relative to outstanding shares.
• The overhang rate of 13.5% (as of March 4, 2026) is also deemed reasonable when compared to industry peers, providing flexibility for future equity awards without excessive dilution.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic transformation and new leadership, but current underperformance in TSR and financial metrics poses a concern. The proposed incentive plan and board size amendment directly impact shareholder rights and potential dilution.
• Employees: Significant leadership transitions, organizational restructuring, and the launch of the Baxter Growth and Performance System (GPS) will impact employee roles, responsibilities, and performance expectations. Retention awards were used for key leaders during transitions.
• Customers: New product introductions (e.g., Welch Allyn Connex 360, Voalte Linq, Hemopatch) aim to enhance care and streamline communication. Expanded supply-assurance programs (e.g., Vizient Inc.) are designed to provide more reliable product access.
• Patients: The company's mission to 'Save and Sustain Lives' is emphasized, with products supporting over 350 million patients worldwide. Operational resilience efforts (post-Hurricane Helene) ensured ongoing supply of critical IV solutions.
• Communities: Corporate responsibility initiatives, including the Baxter Foundation's $2.6 million grant for STEM programs, demonstrate commitment to community engagement and social impact.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on Tuesday, May 5, 2026, at 9:00 a.m. Central Time.
• Stockholders to vote on the election of nine directors, advisory approval of named executive officer compensation for 2025, ratification of PwC as independent auditor for 2026, approval of the Second Amended and Restated 2021 Incentive Plan, and approval of an amendment to the Certificate of Incorporation to amend Board size.
• Andrew Hider and the management team will continue to focus on stabilizing business performance, strengthening execution, thoughtful capital allocation, and long-term value creation.
• Continue progressing toward 'Building the Best Baxter' through the Baxter Growth and Performance System (GPS) and refined operating model.
• William Ampofo will assume the role of Quality and Regulatory Compliance Committee Chair upon Dr. Oesterle's retirement in May 2026.
• Expect to announce refreshed sustainability commitments after the issuance of the 2025 Corporate Responsibility Report.
• Joel Grade will serve in an advisory capacity through April 30, 2026, following his cessation as CFO on March 16, 2026.
• Reazur Rasul will cease serving as Executive Vice President and Group President, Healthcare Systems & Technologies, effective April 1, 2026.

Key Dates

Recommendation

The company is undergoing a significant turnaround with new leadership and strategic divestitures, which are positive long-term steps. However, the substantial underperformance in Total Shareholder Return (TSR) and missed financial targets for 2025, particularly in Free Cash Flow and Relative TSR, indicate that the turnaround is in its very early stages and faces considerable headwinds. While the strategic direction is sound, the execution and realization of value are yet to be proven. The high executive compensation, especially for the new CEO, amidst poor performance could be a point of concern for investors. A 'hold' recommendation is appropriate as investors should monitor the progress of the turnaround initiatives and the impact of new leadership before making further investment decisions.

Keywords

Healthcare, Medical Devices, Pharmaceuticals, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Turnaround Strategy, Divestiture, Kidney Care, Vantive Health, Andrew Hider, Brent Shafer, Stock Options, Restricted Stock Units, Performance Share Units, Financial Performance, Risk Management, Supply Chain, Innovation, Sustainability